
    
      -  Compare 3-year overall survival between concurrent chemoradiotherapy and esophagectomy
           among patients who require additional treatment for esophageal squamous cell carcinoma
           endoscopically resected but found to have pT1b (submucosal invasion) or lymphovascular
           invasion

        -  Compare disease-free survival between concurrent chemoradiotherapy and esophagectomy in
           the same study population

        -  Compare quality of life between concurrent chemoradiotherapy and esophagectomy in the
           same study population

        -  Compare treatment-related adverse event between concurrent chemoradiotherapy and
           esophagectomy in the same study population
    
  